New disease-modifying treatments (DMTs), namely, crizanlizumab, L-glutamine, and voxelotor, have recently been approved.
Sickle Cell Disease patients and the use of disease-modifying treatments
- Post author:
- Post published:November 23, 2023
- Post category:uncategorized